BioLineRx announced that it has licensed an experimental immunotherapy drug from Yissum Research Development Company Ltd which is the business side of Hebrew University of Jerusalem(Israel).

The drug is currently known as “BL-7040” & BioLineRx has plans to further develop & commercialize the drug worldwide. BL-7040 is an experimental drug that is still in testing, but it has already passed Phase Ib & Phase IIa clinical trials. Officially it won’t be known how well BL-7040 works until it’s subjected to Phase IIb clinical trials. However, Prof. Hermona Soreq sounds optimistic on the drug’s efficacy:

The efficacy of BL-7040 in these [earlier] studies was shown to be highly significant and comparable to that of dexamethasone, a steroid used routinely for IBD that has multiple side effects. Continue reading “BioLineRX’s TLR-9 Immunotherapy For Inflammatory Bowel Disease” »